Drug Search Results
More Filters [+]

BRM-421

Alternative Names: brm-421, brm421, brm 421
Latest Update: 2023-09-18
Latest Update Note: Clinical Trial Update

Product Description

BRM421 is a developing topical ophthalmic solution for patients with moderate-to-severe DES.

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BRIM Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BRM-421

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BRM421-22-C001-PR

P3

Recruiting

Keratoconjunctivitis Sicca|Dry Eye Syndromes|Dry Eye Disease

2023-12-30

18%

Recent News Events

Date

Type

Title